Vontobel Holding’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
AIM
OAG
GP
SOCM
Vontobel Holding's CRSP Position: Q1 2026 in Review
Vontobel Holding increased its CRISPR Therapeutics (CRSP) stake by 52% in Q1 2026, buying an estimated $360K and bringing the position to 19,828 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #671.
Vontobel Holding first reported a position in CRSP in Q2 2021 and has held it in 19 quarters since. The position peaked at $2.81M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Vontobel Holding held 19,828 shares of CRISPR Therapeutics worth $943K as of Q1 2026.
- Vontobel Holding bought 6,826 CRISPR Therapeutics shares in Q1 2026, an estimated $360K.
- CRISPR Therapeutics made up ﹤0.01% of Vontobel Holding's portfolio in Q1 2026, its #671 holding.
- Vontobel Holding first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 19 quarters since.
- Vontobel Holding's CRISPR Therapeutics position peaked at $2.81M in Q2 2021.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Vontobel Holding's 13F filing for Q1 2026, filed 8 May 2026.